SCHEMBL5122885

SCHEMBL5122885

C#Cc1ccsc1-c1nc2cnccn2c1NC(=O)c1ccccc1.c1cc2cc-2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.46
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
SYK P43405 1/20 0.44
KMT2A Q03164 3/20 0.44
MAPT P10636 2/20 0.43
GABRD O14764 1/20 0.41
GABRB1 P18505 1/20 0.41
GABRA4 P48169 1/20 0.41
BRAF P15056 2/20 0.40
LMNA P02545 2/20 0.39
MEN1 O00255 1/20 0.39
EGFR P00533 1/20 0.39
ERBB2 P04626 1/20 0.39
KDM4E B2RXH2 1/20 0.38
GAA P10253 1/20 0.38
MAPK1 P28482 1/20 0.38
EPHB2 P29323 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5121924 0.90 MAPT (0.42) SYKKMT2AMAPTLMNAMEN1
SCHEMBL5114310 0.89 SYK (0.40) HSD17B10SYKKMT2AMAPTBRAF
SCHEMBL5127803 0.86 SYK (0.39) HSD17B10SYKKMT2AMAPTBRAF
SCHEMBL5121542 0.85 GAA (0.43) HSD17B10SYKMAPTBRAFLMNA
SCHEMBL5113515 0.84 GAA (0.41) HSD17B10SYKKMT2AMAPTBRAF
SCHEMBL5130362 0.82 CDK9 (0.57) MAPTBRAFKDM4EGAA
SCHEMBL5115036 0.81 GAA (0.49) HSD17B10SYKKMT2AMAPTLMNA
SCHEMBL5118759 0.81 CDK9 (0.41) HSD17B10SYKMAPTBRAFLMNA
SCHEMBL5127406 0.81 SALL4 (0.46) KMT2ABRAFLMNAMEN1KDM4E
SCHEMBL5122233 0.81 BRD4 (0.50) HSD17B10SYKKMT2AMAPTBRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1791840-B1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS GRUENENTHAL GMBH (DE) 2013-11-27 EP claimed
US-7420056-B2 Substituted bicyclic imidazo-3-ylamine compounds GRUENENTHAL GMBH (DE) 2008-09-02 US claimed
US-20070155965-A1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS GRUENENTHAL GMBH. (DE) 2007-07-05 US claimed
US-7420056-B2 Substituted bicyclic imidazo-3-ylamine compounds GRUENENTHAL GMBH (DE) 2008-09-02 US disclosed
US-20070155965-A1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS GRUENENTHAL GMBH. (DE) 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155965-A1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PAICS HSD17B10 3688/4885CYP1A2 250/4885CYP3A4 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.